down arrow

enVVeno Medical Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29415J1060
USD
0.39
0.02 (6.71%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.370.40

52 Week

0.305.62
Valuation
Technical
Day's Volume

CASH

245.09 k

Shareholding (Jun 2025)

FII

3.89%

Held by 13 FIIs

DII

90.63%

Held by 6 DIIs

Promoter

0.00%

How big is enVVeno Medical Corp.?

22-Jun-2025

As of Jun 18, enVVeno Medical Corp. has a market capitalization of 75.23 million, with net sales of 0.00 million and a net profit of -21.33 million over the last four quarters. The company reported shareholder's funds of 42.16 million and total assets of 44.95 million as of Dec 24.

Market Cap: As of Jun 18, enVVeno Medical Corp. has a market capitalization of 75.23 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, enVVeno Medical Corp. reported net sales of 0.00 million and a net profit of -21.33 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 42.16 million and total assets of 44.95 million.

Read More

What does enVVeno Medical Corp. do?

22-Jun-2025

enVVeno Medical Corp. is a development stage medical device company focused on biologic-based solutions for cardiovascular and venous diseases. As of March 2025, it has a market cap of $75.23 million and reported a net profit loss of $5 million.

Overview:<BR>enVVeno Medical Corp. is a development stage medical device company in the Pharmaceuticals & Biotechnology industry, focused on creating biologic-based solutions for patients with cardiovascular and venous diseases.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 75.23 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -55.00% <BR>Price to Book: 1.96 <BR><BR>Contact Details:<BR>Address: 70 Doppler, IRVINE CA 92618-4306 <BR>Tel: 1 949 2612900 <BR>Fax: 1 949 2612992 <BR>Website: http://www.hancockjaffe.com/

Read More

Is enVVeno Medical Corp. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, enVVeno Medical Corp. shows a mildly bearish trend, supported by bearish MACD and moving averages, despite bullish RSI readings, and has significantly underperformed the S&P 500 with a 1-month return of -81.29% and a 1-year return of -81.67%.

As of 3 September 2025, the technical trend for enVVeno Medical Corp. has changed from sideways to mildly bearish. The current stance is bearish overall, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish moving averages on a daily basis, and bearish signals from Dow Theory and KST. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish trend. The stock has significantly underperformed compared to the S&P 500, with a 1-month return of -81.29% versus 2.33% for the index, and a 1-year return of -81.67% compared to 17.14% for the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 15 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-68.62%

stock-summary
Price to Book

0.44

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.27%
0%
-50.27%
6 Months
-88.82%
0%
-88.82%
1 Year
-87.28%
0%
-87.28%
2 Years
-89.07%
0%
-89.07%
3 Years
-93.46%
0%
-93.46%
4 Years
-93.77%
0%
-93.77%
5 Years
-94.76%
0%
-94.76%

enVVeno Medical Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is enVVeno Medical Corp. technically bullish or bearish?

As of 3 September 2025, the technical trend for enVVeno Medical Corp. has changed from sideways to mildly bearish. The current stance is bearish overall, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish moving averages on a daily basis, and bearish signals from Dow Theory and KST. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish trend. The stock has significantly underperformed compared to the S&P 500, with a 1-month return of -81.29% versus 2.33% for the index, and a 1-year return of -81.67% compared to 17.14% for the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-212.07%
EBIT to Interest (avg)
-20.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.75
EV to EBIT
-1.23
EV to EBITDA
-1.26
EV to Capital Employed
-28.59
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-55.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (5.48%)

Foreign Institutions

Held by 13 Foreign Institutions (3.89%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -34.00% vs 23.08% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.90",
          "val2": "-5.30",
          "chgp": "-30.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.70",
          "val2": "-5.00",
          "chgp": "-34.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.23% vs 4.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-24.70",
          "chgp": "5.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.80",
          "val2": "-23.50",
          "chgp": "7.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.90
-5.30
-30.19%
Interest
0.00
0.00
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-6.70
-5.00
-34.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -34.00% vs 23.08% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-23.30
-24.70
5.67%
Interest
0.00
0.00
Exceptional Items
-0.00
0.50
-100.00%
Consolidate Net Profit
-21.80
-23.50
7.23%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.23% vs 4.86% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About enVVeno Medical Corp. stock-summary
stock-summary
enVVeno Medical Corp.
Pharmaceuticals & Biotechnology
Hancock Jaffe Laboratories, Inc. is a development stage medical device company. The Company is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The Company is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.
Company Coordinates stock-summary
Company Details
70 Doppler , IRVINE CA : 92618-4306
stock-summary
Tel: 1 949 2612900
stock-summary
http://www.hancockjaffe.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."